MRNA Stock Price Moderna Inc Stock Quote U.S.: Nasdaq

what is moderna stock

Moderna has got some promising news on the coronavirus vaccine front. (MRNA) raised $499 million in an initial public offering on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers. Elis announces the signing of an agreement for the acquisition of Moderna Holding BV in the Netherlands Saint-Cloud, 10 January 2024 – Elis, the global leader in circular services at work, today annou… An approved RSV vaccine on the market this year looks likely, but investors worry about efficacy.

what is moderna stock

Cases in highly-inoculated Israel are also up by almost 10x over the last month. Research is also showing that protection provided by Covid-19 vaccines begins to wane after several months. These developments are making a real case for booster vaccinations and Moderna is perfectly poised to cater to this market with its mRNA technology which can be more quickly adapted to fight new variants. This could mean that Moderna’s highly lucrative Covid-19 vaccine revenues are likely to continue for the foreseeable future (rather than just being a one-off pandemic product), likely causing investors to re-rate the stock higher. Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics.

MRNA Stock Analysis – Frequently Asked Questions

There are currently 2 sell ratings, 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “hold” MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or bitfinex review sell existing shares. Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature’s DNA to other parts of the body.

Now, Moderna is looking ahead to its respiratory syncytial virus vaccine. The company expects to gain Food and Drug Administration approval in the first half of the year, vs. earlier coinberry review guidance for April. Worries about waning effectiveness, though, have hammered Moderna stock. If approved, the vaccine will launch a year after Pfizer’s and GSK’s (GSK) shots.

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases. Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors.

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company’s weighted average against that of other companies. Metagenomi Technologies, a genetic medicines company backed by Moderna , said on Monday it was targeting a valuation of up to fusion markets review $638 million for its initial public offering in New York. Hedge funds with long/short strategies have benefited in 2024 from a macroeconomic environment that has hit the most heavily shorted stocks particularly hard compared to their less shorted rivals, a n… Moderna reiterated its full-year 2024 sales guidance of roughly $4 billion.

More importantly, Moderna’s vaccine cash cow will give it the ability to fund its research pipelines in the years to come. The company is developing nine vaccines and 13 therapeutic candidates in areas including immuno-oncology and rare diseases. Four of the company’s developments, including its CMV vaccine and personalized cancer vaccine, are in phase 2 trials. Overall, the strong momentum following the S&P inclusion, continuing prospects for the Covid-19 shot, and upside from Moderna’s pipeline could mean that a rally to $400 isn’t looking like a stretch for Moderna stock. Booster and potentially annual doses should be positive for Covid vaccine makers, in general, as they could likely see some level of recurring revenues from what initially appeared like a one-off vaccine. This should be particularly positive for Moderna which counts its Covid-19 shot as its only revenue-generating product at the moment.

The company is now looking to launch its second product, a respiratory syncytial virus vaccine for older adults. The cancer vaccine reduced the likelihood cancer would return or patients would die after about three years. A Phase 3 study is already underway with the initial results expected later this decade. But at least one analyst says Moderna could seek a speedy approval in 2025.

Moderna (MRNA) Q3 2023 Earnings Call Transcript

For example, Novavax NVAX has a cheap and highly effective shot, that’s likely to be approved for use later this year and it is possible that there are going to be more vaccines available in the coming years if Covid-19 becomes endemic. The consensus estimate for Moderna’s 2022 revenues points to a revenue decline of about -16%. If vaccine sales show signs of slowing, which we eventually believe they will, investors are likely to re-rate the stock lower. Covid-19 vaccines have proven to be highly effective in preventing serious illness and hospitalization, but experts have increasingly warned that overly high revenue expectations set last year may not be sustainable as the pandemic wanes. As Moderna shares plunged in January, Meacham upgraded the stock from underperform to neutral and lifted his price target to $180 from $135, telling investors the firm’s valuation was finally “back to earth.” Moderna stock currently trades at a mere 12x 2021 consensus earnings.

  1. Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55 Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP dilute…
  2. Moderna is also looking to scale up its production capacity to as much as 3 billion doses in 2022, up from roughly 1 billion doses in 2021, and recently outlined plans to add two new production lines at its plant in Boston.
  3. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
  4. Governments also aren’t taking any chances, choosing to lock in future vaccine supplies given what’s at stake from a healthcare and economic standpoint, if the virus persists.
  5. Sales of Moderna’s Spikevax COVID vaccine came to $2.8 billion in the fourth quarter and totaled $6.7 billion for fiscal 2023, whereas the company had previously said it expected full-year sales of at least $6 billion.

CNBC’s Jim Cramer explains why he is keeping an eye on shares of Moderna.

A lot is riding on whether there will be demand for its new vaccines.

Encouraging news coming out of the biotech regarding its coronavirus vaccine candidate caused its stock to pop. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on, top-rated podcasts, and non-profit The Motley Fool Foundation. Moderna (MRNA) posted a fourth-quarter profit after beating revenue and earnings estimates. A large part of the rise in Moderna stock in recent weeks has come from the momentum following the company’s inclusion into the S&P 500 in mid-July. This likely led to index funds tracking the index, as well as funds benchmarked to the index, buying into Moderna stock.

The company posted quarterly revenue of $2.8 billion for its Covid-19 vaccine, including $800 million in U.S. sales and $2 billion of international sales. While that was about a 45% decline from a year ago, it topped analysts’ estimates of $2.5 billion. Fourth-quarter sales included $600 million in deferred revenue related to Moderna’s work with GAVI, a global health initiative to boost immunization. See our indicative theme of  Covid-19 Vaccine stocks which includes U.S.-based pharma and biotech companies. The theme is up by about 25% year-to-date, compared to the S&P 500, which is up by about 10%. Moreover, many experts think that Covid is likely to become endemic with the virus continuing to mutate, potentially making Covid vaccine shots an annual occurrence, much like flu shots.

Elis closes the acquisition of Moderna Holding BV in the Netherlands Saint-Cloud, 26 February 2024 – Elis, the global leader in circular services at work, today announces the acquisition of 100% of Mo… Moderna operates a very modern plant that becomes one of the largest plants of the Group. Thanks to 2 supply centers, the plant can address the entire Dutch territory. It provides Flat linen, Workwear, and Hygiene & Well-being services to clients in the Hospitality, Industrial, and Trade & Services industries. To find the best stocks to buy and watch, check out IBD Stock Lists. The RS Rating is a 1-99 measure of a stock’s 12-month performance.

Moderna (MRNA) , a clinical-stage biotech company, is carrying out phase 3 trials of its Covid-19 vaccine, completing enrollment of 30,000 participants. The company is likely to have data on whether its vaccine works or not by this month, and has noted that it would seek emergency approval from the FDA if the vaccine is at least 70% effective. Moderna Inc. shares shot up in trading after the company reported fourth-quarter revenue that beat analysts’ expectations by gaining Covid vaccine market share on its rival, Pfizer Inc. There is unlikely to be any new clinical trial data or product launches from Moderna’s portfolio that are capable of convincing investors that the business is worth as much in 2024 as it was in 2021 or 2022.

COVID-19 vaccine

The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020. Moderna reported a profit of 55 cents a share on revenue of $2.8 billion in the December quarter, beating analysts’ expectations. As the leader in circular services, thanks to a rental-maintenance model optimized by traceability technologies, Elis innovates every day. In its 29 countries, Elis meets the needs of its customers in terms of protection, hygiene, and well-being, while assisting them in achieving their environmental objectives. With unique operational know-how and a profitable organic growth profile, Elis creates sustainable value for its shareholders, customers, employees, and the environment.

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Stéphane Bancel has an approval rating of 92% among the company’s employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *